“Novel protocol combining metronomic Nant-paclitaxel with
HER2-targeted natural killer cells (innate immunotherapy) for
HER2-positive metastatic breast cancer”
CULVER CITY, Calif.--(BUSINESS WIRE)--Dec. 9, 2015--
NantKwest Inc. (Nasdaq:NK), a pioneering, next generation,
clinical-stage immunotherapy company focused on harnessing the unique
power of our immune system using natural killer (NK) cells to treat
cancer, infectious diseases and inflammatory diseases and NantCell, an
immuno-oncology company focused on the discovery of innovative
molecularly targeted therapeutics, announced today that preclinical
results from the company’s HER2.taNK program will presented at the San
Antonio Breast Cancer Symposium (SABCS), December 8-12, 2015, in San
Antonio, Texas.
"NantKwest is focused on bringing transformative, NK cell-based
therapies to cancer patients that are designed to dramatically improve
clinical outcomes. We will be presenting data from this recently
completed research study in collaboration with the Windber Medical
Center and NantCell at the upcoming SABCS meeting that demonstrates the
synergistic use of low dose, metronomic Nant-paclitaxel in combination
with our NK cell-based therapy,” said Patrick Soon-Shiong, MD, Chairman
and CEO of NantKwest. "The results of this study supports the foundation
for our HER2.taNK program, as well as several additional therapeutic
programs that will transition to human clinical trials in 2016. We look
forward to sharing more specific details on our clinical trial plans in
the next few months.”
Details of the presentations are listed below and available on the SABCS
website:
Title: “Novel protocol combining metronomic Nant-paclitaxel with
HER2-targeted natural killer cells (innate immunotherapy) for
HER2-positive metastatic breast cancer”
Poster Session: Thursday, December 10, 2015, Poster Session 2:
Treatment: Immunotherapy (Clinical) (7:30 AM-9:00 AM)
Authors: Rabizadeh S, Simon B, Klingemann H, Sims D, Weiss R,
Soon-Shiong P. NantCell, Inc, Culver City, CA; NantKwest, Inc, Culver
City, CA; Windber Medical Center, Windber, PA
Conclusion
Results show that Nant-paclitaxel alone and HER2.taNK alone
significantly inhibited tumor growth. The combination of Nant-paclitaxel
+ HER2.taNK led to significant tumor regressions (p<0.05). Abstracts are
available to the public online on the SABCS website: www.sabcs.org.
About NantKwest Inc.
NantKwest (Nasdaq:NK) is a pioneering, next generation, clinical-stage
immunotherapy company focused on harnessing the unique power of our
immune system using natural killer (NK) cells to treat cancer,
infectious diseases and inflammatory diseases. NK cells are the body’s
first line of defense due to the innate ability of NK cells to rapidly
identify and destroy cells under stress, such as cancer or
virally-infected cells.
NantKwest’s unique NK cell-based platform, with the capacity to grow
active killer cells as a biological cancer therapy, has been designed to
induce cell death against cancer or infected cells by three different
modes of action: (1) Direct killing using activated NK cells (aNK) that
release toxic granules directly into the cell through cell to cell
contact, (2) Antibody-mediated killing using haNKs, which are NK cells
engineered to incorporate a high affinity receptor that binds to an
administered antibody, enhancing the cancer cell killing effect of that
antibody, and (3) Targeted activated killing using taNKs, which are NK
cells engineered to incorporate chimeric antigen receptors (CARs) to
target tumor-specific antigens found on the surface of cancer cells.
Our aNK, haNK and taNK platform addresses certain limitations of T cell
therapies including the reduction of risk of serious "cytokine storms"
reported after T cell therapy. As an “off-the-shelf” therapy,
NantKwest's NK cells do not rely on a patient’s own often compromised
immune system. In Phase 1 clinical trials in patients with late stage
cancer, NantKwest's NK cells have been successfully administered as an
outpatient infusion therapy without any reported severe side effects,
even at doses of 10 billion cells.
By leveraging an integrated and extensive genomics and transcriptomics
discovery and development engine, together with a pipeline of multiple,
clinical-stage, immuno-oncology programs that include a Phase 2 trial
for a rare form of melanoma and the planned initiation of a clinical
trial of NK cells targeted to breast cancer, we believe NantKwest is
uniquely positioned to be the premier immunotherapy company and
transform medicine by delivering living drugs in a bag and bringing
novel NK cell-based therapies to routine clinical care. For more
information please visit http://www.nantkwest.com
and follow Dr. Soon-Shiong on Twitter @solvehealthcare.
About NantCell
NantCell, a wholly-owned subsidiary of NantWorks, LLC, is an
immuno-oncology company focused on the discovery and development of
innovative, molecularly targeted immunotherapeutics based on the
proteomic profile of the patient's tumor, independent of the cancer's
anatomical type. Dr. Patrick Soon-Shiong, the creator of Abraxane® and
the founder of the nab® technology platform established NantCell to
develop a pipeline of human antibodies and inhibitors of proteins which
drive tumor growth and pursue the development of Chimeric Receptor
Antigen platforms for use in both T cell and NK cell therapy. NantCell's
mission is to make obsolete the standard method of clinical trial design
of "trial and error" and replace it with a level of quantitative
predictability based on both the genomic and proteomic profile performed
a priori. The Company will tap into comprehensive “omic” analytic tools
and "big data" generated from supercomputing to develop molecularly
designed drugs in this era of genomics and proteomics and identify
patients and their tumor signature at the most granular cellular, DNA
and protein levels. Patients entering clinical trials would be
identified after a comprehensive “omic” analysis from tissue to cell to
DNA to RNA to protein to peptide to drug, and tested based on this
molecular profile to maximize clinical outcome and minimize side
effects. Through these integrated diagnostic methods, the company is
pursuing the vision of treating the biology of cancer rather than the
anatomy, and drive the immune system inherited by all to defeat cancer.
For more information please visit www.nanthealth.com and
follow Dr. Soon-Shiong on Twitter @solvehealthcare.
About NantWorks
NantWorks, LLC, founded by renowned physician scientist and inventor of
the first human nanoparticle chemotherapeutic agent Abraxane®, Dr.
Patrick Soon-Shiong, is the umbrella organization for the following
entities: NantHealth, NantMobileHealth, NantOmics, NantBio, NantCell,
NantPharma, NantCapital and NantCloud. Fact-based and solution-driven,
each of NantWorks’ division entities operates at the nexus of innovation
and infrastructure.
The core mission of NantWorks is convergence and a systems approach to
human biology: to develop and deliver a diverse range of technologies
that accelerates innovation, broaden the scope of scientific discovery,
enhance ground-breaking research, and improve healthcare treatment for
those in need. NantWorks is building an integrated fact-based,
genomically and proteomically -informed, personalized approach to the
delivery of care and the development of next generation diagnostics and
therapeutics for life threatening diseases such as Cancer, Infectious
Diseases and Alzheimer’s. For more information please visit www.nantworks.com
and follow Dr. Soon-Shiong on Twitter @solvehealthcare.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151209005450/en/
Source: NantKwest
NantWorks
Jen Hodson, 562-397-3639
jhodson@nantworks.com